NEUROSENSE THERAPEUTICS LTD (NRSN)

IL0011809592 - Common Stock

1.24  -0.03 (-2.36%)

Fundamental Rating

0

NRSN gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. NRSN may be in some trouble as it scores bad on both profitability and health. NRSN does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NRSN has reported negative net income.
NRSN had a negative operating cash flow in the past year.
NRSN had negative earnings in each of the past 5 years.
NRSN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of NRSN (-355.35%) is worse than 94.87% of its industry peers.
Industry RankSector Rank
ROA -355.35%
ROE N/A
ROIC N/A
ROA(3y)-183.52%
ROA(5y)-208.09%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NRSN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

NRSN has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, NRSN has a worse debt to assets ratio.

2.2 Solvency

NRSN has an Altman-Z score of -25.55. This is a bad value and indicates that NRSN is not financially healthy and even has some risk of bankruptcy.
NRSN's Altman-Z score of -25.55 is on the low side compared to the rest of the industry. NRSN is outperformed by 89.57% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -25.55
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 0.84 indicates that NRSN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.84, NRSN is doing worse than 91.11% of the companies in the same industry.
A Quick Ratio of 0.84 indicates that NRSN may have some problems paying its short term obligations.
NRSN has a worse Quick ratio (0.84) than 90.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.84

More info and screens

1

3. Growth

3.1 Past

NRSN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.21%, which is quite impressive.
EPS 1Y (TTM)29.21%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q36.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 2.90% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.88%
EPS Next 2Y2.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NRSN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRSN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.9%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NRSN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROSENSE THERAPEUTICS LTD

NASDAQ:NRSN (5/7/2024, 2:53:38 PM)

1.24

-0.03 (-2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap21.49M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -355.35%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.84
Quick Ratio 0.84
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)29.21%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y5.88%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y